{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:19Z","timestamp":1790660179524,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are rare diseases, they pose a significant burden on both society and the healthcare system. This study aims to discuss the demographics and patient characteristics of these diseases in a single center in the United Arab Emirates (UAE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective, descriptive study that included patients with either NMOSD or MOGAD treated at Rashid Hospital, UAE during the period between January 2019 and January 2024. Patients were selected and categorized according to NMOSD criteria, aquaporin-4 antibodies, and MOG antibodies. Patient demographics, clinical characteristics, and medical history were retrieved from their medical records and descriptively analyzed in the light of patients\u2019 serological data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 34 patients with non-multiple sclerosis atypical CNS inflammatory\/demyelinating syndromes. Twenty-seven patients (79.4%) fulfilled the criteria for NMOSD, while seven (20.6%) tested positive for MOG antibodies, fulfilling the criteria for MOGAD. In the NMOSD cohort, 19% (<jats:italic>n<\/jats:italic>\u2009=\u20095) were AQP4-antibody negative. Seventy-four percent of the NMOSD cohort and 43% of the MOGAD cohort were female. For MOGAD patients, disease onset was at a younger age (median onset age of 25\u2009years) compared to the overall study population (mean onset age of 28.94\u2009years). Long segment transverse myelitis was only detected in NMOSD patients (33.3%), and brainstem syndrome with area postrema syndrome was more common in the MOGAD cohort (29% vs. 4%). The rate of positive response to intravenous methylprednisolone as initial therapy was comparable across both cohorts (74% in case of NMOSD and 71% in case of MOGAD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides valuable insights into the status of NMOSD and MOGAD in the UAE, highlighting the need for larger, prospective studies to further characterize these diseases in the local population, as well as the need for improved understanding of the epidemiology and management of these rare but debilitating conditions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1480723","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:02:45Z","timestamp":1733760165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["MOGAD and NMOSD: insights on patients\u2019 radiological and laboratory findings from a single UAE center"],"prefix":"10.3389","volume":"15","author":[{"given":"Hamdan","family":"Alzarooni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Inshasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies","volume":"11","author":"Asseyer","year":"2020","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J Neuroinflammation"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scl"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1137998","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Siritho","year":"2023","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/WNL.0b013e3182887957","article-title":"Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution","volume":"80","author":"Matthews","year":"2013","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cen3.12630","article-title":"Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G\u2013associated disease","volume":"12","author":"Healy","year":"2021","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/s-0043-102456","article-title":"NMO spectrum disorder","author":"Kawachi","year":"2015","journal-title":"Nihon Rinsho"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21145021","article-title":"Differential effects of MS therapeutics on b cells\u2014implications for their use and failure in AQP4-positive NMOSD patients","volume":"21","author":"Traub","year":"2020","journal-title":"IJMS"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14712598.2020.1749259","article-title":"Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders","volume":"20","author":"Duchow","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/cen3.12458","article-title":"Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: a multicenter, retrospective study","volume":"9","author":"Holroyd","year":"2018","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"101448","DOI":"10.1016\/j.msard.2019.101448","article-title":"Neuromyelitis optica spectrum disorders in Arabian gulf (NMOAG); establishment and initial characterization of a patient registry","volume":"38","author":"Shosha","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1260358","article-title":"Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide","volume":"14","author":"Hor","year":"2023","journal-title":"Front Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2055217319850195","DOI":"10.1177\/2055217319850195","article-title":"Neuromyelitis optica spectrum disorders in the Arabian gulf: challenges and growing experience","volume":"6","author":"Alroughani","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.msard.2017.10.007","article-title":"Neuromyelitis optica spectrum disorders in Iran","volume":"18","author":"Eskandarieh","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"104498","DOI":"10.1016\/j.msard.2023.104498","article-title":"Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder","volume":"70","author":"Smith","year":"2023","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Clin Pract Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","article-title":"Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD","volume":"59","author":"Yan","year":"2016","journal-title":"Sci China Life Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.msard.2018.11.031","article-title":"Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD)","volume":"27","author":"Fragoso","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"578035","DOI":"10.1016\/j.jneuroim.2023.578035","article-title":"The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab","volume":"376","author":"Gou","year":"2023","journal-title":"J Neuroimmunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"14559","DOI":"10.3390\/ijms232314559","article-title":"AQP4-MOG double-positive Neuromyelitis Optica Spectrum disorder: case report with central and peripheral nervous system involvement and review of literature","volume":"23","author":"Spiezia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/bs.irn.2022.06.011","article-title":"Sex and gender differences in autoimmune demyelinating CNS disorders: multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD)","author":"Diem","year":"2022","journal-title":"Int Rev Neurobiol"},{"key":"ref30","first-page":"474","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume-title":"Neurology","author":"Sato","year":"2014"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"117225","DOI":"10.1016\/j.jns.2020.117225","article-title":"Neuromyelitis optica spectrum disorders","volume":"420","author":"Paul","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives","volume":"18","author":"D'Amico","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol [Internet]"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.873576","article-title":"Neuromyelitis Optica Spectrum disorder with anti-Aquaporin-4 antibody: outcome prediction models","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1480723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:02:49Z","timestamp":1733760169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1480723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":35,"alternative-id":["10.3389\/fneur.2024.1480723"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1480723","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"article-number":"1480723"}}